Biogen Company Profile (NASDAQ:BIIB)

About Biogen

Biogen logoBiogen Inc., formerly Biogen Idec Inc., is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc., a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies. It also develops late stage product candidates, including Aducanumab (BIIB037) for the treatment of Neurodegeneration, and Nusinersen for other programs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: BIIB
  • CUSIP: 09062X10
Key Metrics:
  • Previous Close: $306.13
  • 50 Day Moving Average: $295.87
  • 200 Day Moving Average: $270.20
  • 52-Week Range: $223.02 - $333.65
  • Trailing P/E Ratio: 17.97
  • Foreward P/E Ratio: 14.81
  • P/E Growth: 1.60
  • Market Cap: $67.40B
  • Outstanding Shares: 219,120,000
  • Beta: 0.93
Additional Links:
Companies Related to Biogen:

Analyst Ratings

Consensus Ratings for Biogen (NASDAQ:BIIB) (?)
Ratings Breakdown: 10 Hold Ratings, 12 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.61)
Consensus Price Target: $346.61 (12.59% upside)

Analysts' Ratings History for Biogen (NASDAQ:BIIB)
DateFirmActionRatingPrice TargetDetails
8/23/2016Jefferies GroupReiterated RatingBuyView Rating Details
8/17/2016Morgan StanleyLower Price TargetOverweight$385.00 -> $368.00View Rating Details
8/16/2016Piper Jaffray Cos.Reiterated RatingNeutral$293.00 -> $333.00View Rating Details
8/10/2016Robert W. BairdReiterated RatingNeutral$284.00View Rating Details
8/9/2016Leerink SwannReiterated RatingHold$367.00View Rating Details
8/3/2016Credit Suisse Group AGReiterated RatingHold$322.00View Rating Details
8/2/2016Standpoint ResearchDowngradeBuy -> HoldView Rating Details
8/2/2016Raymond James Financial Inc.Boost Price TargetStrong-Buy$360.00 -> $375.00View Rating Details
8/1/2016BMO Capital MarketsBoost Price TargetMarket Perform$286.00 -> $304.00View Rating Details
7/24/2016HC WainwrightReiterated RatingBuy$360.00View Rating Details
6/30/2016Bank of America Corp.Reiterated RatingBuyView Rating Details
6/29/2016Sanford C. BernsteinInitiated CoverageOutperform$282.00View Rating Details
6/8/2016Royal Bank Of CanadaReiterated RatingBuyView Rating Details
6/8/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details
6/7/2016Citigroup Inc.DowngradeBuy -> Neutral$345.00 -> $295.00View Rating Details
5/26/2016Cowen and CompanyReiterated RatingBuyView Rating Details
4/23/2016Goldman Sachs Group Inc.Reiterated RatingHoldView Rating Details
4/21/2016Stifel NicolausReiterated RatingHoldView Rating Details
1/27/2016JPMorgan Chase & Co.Reiterated RatingOverweight$403.00View Rating Details
1/27/2016William BlairReiterated RatingOutperformView Rating Details
1/22/2016Barclays PLCReiterated RatingBuy$420.00View Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageOverweight$344.00View Rating Details
9/23/2015Oppenheimer Holdings Inc.Reiterated RatingSector PerformView Rating Details
8/11/2015Deutsche Bank AGReiterated RatingBuyView Rating Details
7/27/2015ArgusLower Price TargetBuy$450.00 -> $360.00View Rating Details
6/9/2015GuggenheimInitiated CoverageNeutralView Rating Details
4/27/2015NomuraReiterated RatingNeutral$401.00 -> $442.00View Rating Details
12/3/2014S&P Equity ResearchReiterated RatingBuyView Rating Details
(Data available from 8/30/2014 forward)


Earnings History for Biogen (NASDAQ:BIIB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/21/2016Q216$4.69$5.21$2.79 billion$2.89 billionViewListenView Earnings Details
4/21/2016Q116$4.47$4.79$2.75 billion$2.73 billionViewListenView Earnings Details
1/27/2016Q415$4.08$4.50$2.70 billion$2.84 billionViewListenView Earnings Details
10/21/2015Q315$3.80$4.48$2.65 billion$2.39 billionViewListenView Earnings Details
7/24/2015Q215$4.10$4.22$2.71 billion$2.59 billionViewListenView Earnings Details
4/24/2015Q115$3.91$3.82$2.66 billion$2.56 billionViewListenView Earnings Details
1/29/2015Q414$3.77$4.09$2.64 billion$2.60 billionViewListenView Earnings Details
10/22/2014Q3$3.22$3.80$2.48 billion$2.50 billionViewListenView Earnings Details
7/23/2014Q214$2.81$3.49$2.14 billion$2.42 billionViewListenView Earnings Details
4/23/2014Q114$2.56$2.47$2.00 billion$2.10 billionViewListenView Earnings Details
1/29/2014Q413$2.27$2.34$1.93 billion$2.00 billionViewListenView Earnings Details
10/28/2013Q313$2.10$2.35$1.78 billion$1.83 billionViewListenView Earnings Details
7/25/2013Q2 2013$1.93$2.30$1.62 billion$1.70 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.63$1.97$1.41 billion$1.40 billionViewListenView Earnings Details
1/28/2013Q4 2012$1.46$1.40$1.38 billion$1.40 billionViewListenView Earnings Details
10/25/2012$1.60$1.91ViewN/AView Earnings Details
7/24/2012$1.56$1.82ViewN/AView Earnings Details
5/1/2012$1.49$1.40ViewN/AView Earnings Details
1/31/2012$1.49$1.51ViewN/AView Earnings Details
10/28/2011$1.52$1.61ViewN/AView Earnings Details
7/26/2011$1.36$1.36ViewN/AView Earnings Details
4/21/2011$1.41$1.43ViewN/AView Earnings Details
2/1/2011$1.23$1.42ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Biogen (NASDAQ:BIIB)
Current Year EPS Consensus Estimate: $20.11 EPS
Next Year EPS Consensus Estimate: $20.79 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20165$3.82$4.71$4.40
Q2 20164$4.41$4.74$4.62
Q3 20164$4.49$5.18$4.79
Q4 20164$4.81$5.17$5.07
Q1 20171$5.12$5.12$5.12
Q2 20171$5.19$5.19$5.19
Q3 20171$5.08$5.08$5.08
Q4 20172$4.94$5.06$5.00
(Data provided by Zacks Investment Research)


Dividend History for Biogen (NASDAQ:BIIB)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Biogen (NASDAQ:BIIB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/21/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
6/6/2016Adam KoppelEVPSell555$290.00$160,950.00View SEC Filing  
6/3/2016George A ScangosCEOSell842$290.00$244,180.00View SEC Filing  
6/1/2016George A ScangosCEOSell3,855$289.74$1,116,947.70View SEC Filing  
5/25/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
5/2/2016George A ScangosCEOSell487$274.74$133,798.38View SEC Filing  
4/6/2016Adam KoppelEVPSell102$275.00$28,050.00View SEC Filing  
4/6/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
4/1/2016George A ScangosCEOSell487$258.83$126,050.21View SEC Filing  
3/1/2016George A ScangosCEOSell487$261.37$127,287.19View SEC Filing  
2/25/2016Adriana KaraboutisEVPSell84$261.90$21,999.60View SEC Filing  
2/25/2016Alfred SandrockCMOSell183$261.90$47,927.70View SEC Filing  
2/17/2016Alfred SandrockChief Medical OfficerSell722$256.16$184,947.52View SEC Filing  
2/17/2016George A ScangosCEOSell487$256.16$124,749.92View SEC Filing  
2/9/2016Alfred SandrockChief Medical OfficerSell852$246.54$210,052.08View SEC Filing  
12/4/2015Alfred SandrockCMOSell441$277.00$122,157.00View SEC Filing  
10/23/2015Alexander J DennerDirectorBuy310,000$277.47$86,015,700.00View SEC Filing  
7/27/2015Stelios PapadopoulosDirectorBuy10,000$304.88$3,048,800.00View SEC Filing  
6/19/2015Douglas E WilliamsEVPSell3,841$410.00$1,574,810.00View SEC Filing  
6/1/2015George A ScangosCEOSell1,362$398.87$543,260.94View SEC Filing  
4/1/2015George A ScangosCEOSell1,362$423.20$576,398.40View SEC Filing  
3/25/2015John CoxEVPSell12,010$449.06$5,393,210.60View SEC Filing  
3/20/2015Eric K RowinskyDirectorSell11,667$475.00$5,541,825.00View SEC Filing  
3/19/2015Eric K RowinskyDirectorSell2,333$436.14$1,017,514.62View SEC Filing  
3/17/2015Eric K RowinskyDirectorSell4,667$425.45$1,985,575.15View SEC Filing  
3/10/2015Robert W PangiaDirectorSell3,625$413.40$1,498,575.00View SEC Filing  
3/2/2015Alfred SandrockSVPSell3,174$409.49$1,299,721.26View SEC Filing  
2/17/2015Steven H HoltzmanEVPSell2,128$389.11$828,026.08View SEC Filing  
2/10/2015Alfred SandrockSVPSell1,143$398.11$455,039.73View SEC Filing  
2/2/2015Kenneth DipietroEVPSell1,656$389.03$644,233.68View SEC Filing  
12/15/2014Spyridon Artavanis-TsakonasSVPSell1,981$346.50$686,416.50View SEC Filing  
12/2/2014Steven H HoltzmanEVPSell1,749$335.65$587,051.85View SEC Filing  
11/11/2014Steven H HoltzmanEVPSell1,750$330.00$577,500.00View SEC Filing  
11/3/2014George A ScangosCEOSell1,128$320.78$361,839.84View SEC Filing  
10/1/2014George A ScangosCEOSell1,127$330.97$373,003.19View SEC Filing  
10/1/2014Steven H HoltzmanEVPSell1,750$330.97$579,197.50View SEC Filing  
8/1/2014George A ScangosCEOSell1,128$332.93$375,545.04View SEC Filing  
7/16/2014George A ScangosCEOSell12,316$312.37$3,847,148.92View SEC Filing  
5/19/2014Steven HoltzmanEVPSell1,221$289.15$353,052.15View SEC Filing  
5/1/2014George ScangosCEOSell2,123$285.56$606,243.88View SEC Filing  
4/17/2014Steven HoltzmanEVPSell1,221$291.00$355,311.00View SEC Filing  
4/1/2014George ScangosCEOSell2,123$308.42$654,775.66View SEC Filing  
4/1/2014Robert PangiaDirectorSell6,250$308.42$1,927,625.00View SEC Filing  
3/31/2014Brian PosnerDirectorSell3,000$296.76$890,280.00View SEC Filing  
3/20/2014Caroline DorsaDirectorSell10,000$348.88$3,488,800.00View SEC Filing  
3/19/2014Douglas WilliamsEVPSell3,505$352.29$1,234,776.45View SEC Filing  
3/17/2014Steven HoltzmanEVPSell1,221$334.83$408,827.43View SEC Filing  
3/11/2014Stuart KingsleyEVPSell8,428$336.83$2,838,803.24View SEC Filing  
3/3/2014George ScangosCEOSell2,942$335.79$987,894.18View SEC Filing  
2/26/2014Alfred SandrockSVPSell1,048$342.17$358,594.16View SEC Filing  
2/18/2014Steven HoltzmanEVPSell1,222$327.90$400,693.80View SEC Filing  
2/13/2014Kenneth DipietroEVPSell1,290$316.81$408,684.90View SEC Filing  
2/11/2014Alfred SandrockSVPSell2,085$314.31$655,336.35View SEC Filing  
2/11/2014George ScangosCEOSell2,456$314.31$771,945.36View SEC Filing  
2/4/2014Kenneth DipietroEVPSell1,655$299.01$494,861.55View SEC Filing  
1/21/2014Eric RowinskyDirectorSell2,020$310.09$626,381.80View SEC Filing  
1/15/2014Lynn SchenkDirectorSell1,000$297.48$297,480.00View SEC Filing  
1/8/2014William YoungDirectorSell15,000$285.11$4,276,650.00View SEC Filing  
1/6/2014Robert PangiaDirectorSell6,250$278.03$1,737,687.50View SEC Filing  
12/2/2013Lynn SchenkDirectorSell1,000$291.71$291,710.00View SEC Filing  
11/22/2013Raymond PawlickiSVPSell4,000$288.00$1,152,000.00View SEC Filing  
11/1/2013George A ScangosCEOSell2,239$245.57$549,831.23View SEC Filing  
11/1/2013Lynn SchenkDirectorSell1,000$245.00$245,000.00View SEC Filing  
10/22/2013Alfred SandrockSVPSell15,030$250.11$3,759,153.30View SEC Filing  
9/18/2013Paul ClancyCFOSell26,785$245.00$6,562,325.00View SEC Filing  
9/17/2013Steven HoltzmanEVPSell3,501$238.98$836,668.98View SEC Filing  
9/16/2013Paul ClancyCFOSell99,030$238.27$23,595,878.10View SEC Filing  
9/16/2013Raymond PawlickiSVPSell4,000$238.03$952,120.00View SEC Filing  
9/3/2013George ScangosCEOSell2,239$214.40$480,041.60View SEC Filing  
8/26/2013Douglas WilliamsEVPSell4,368$211.35$923,176.80View SEC Filing  
8/1/2013George A ScangosCEOSell2,239$218.82$489,937.98View SEC Filing  
7/16/2013George A ScangosCEOSell2,239$223.94$501,401.66View SEC Filing  
6/14/2013Alexander J DennerDirectorSell2,900$212.00$614,800.00View SEC Filing  
6/11/2013Brian S PosnerDirectorSell2,020$219.62$443,632.40View SEC Filing  
6/10/2013Lynn SchenkDirectorSell2,000$225.82$451,640.00View SEC Filing  
6/3/2013George A ScangosCEOSell1,598$234.16$374,187.68View SEC Filing  
6/3/2013Stephen A SherwinDirectorSell12,825$233.26$2,991,559.50View SEC Filing  
5/28/2013Robert W PangiaDirectorSell5,900$237.23$1,399,657.00View SEC Filing  
12/27/2012Alexander J DennerDirectorSell7,980$148.62$1,185,987.60View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Biogen (NASDAQ:BIIB)
DateHeadline logoCan Biogen Inc Survive with its MS Portfolio? - TCC (NASDAQ:BIIB) - August 30 at 3:49 PM
News IconIntraday Active Biotech Stocks News: CytRx (CYTR), Biogen (NASDAQ:BIIB) - The Voice Registrar (NASDAQ:BIIB) - August 30 at 3:49 PM
News Icon2 Stocks Attracting Analyst Attention: Biogen Inc (NASDAQ:BIIB), The Western Union Company (NYSE:WU) - The Voice Registrar (NASDAQ:BIIB) - August 30 at 3:49 PM logoTop 10 Biotech Stocks for 2016 (ALXN, ALNY) (NASDAQ:BIIB) - August 30 at 3:49 PM logoBiogen Is Setting Up for a Rare Low-Risk Buying Opportunity (NASDAQ:BIIB) - August 30 at 8:46 AM logoCan Biogen Inc Survive with its MS Portfolio? (NASDAQ:BIIB) - August 29 at 8:37 AM logoWhat Should We Expect from BioMarin’s Kuvan in 2016? (NASDAQ:BIIB) - August 26 at 11:56 AM
News IconFirst Mercantile Trust Co Lowers stake in Biogen Inc (BIIB) (NASDAQ:BIIB) - August 25 at 9:17 PM logoWhat’s BioMarin’s Expected Revenue Growth in 2016 and 2017? (NASDAQ:BIIB) - August 25 at 3:54 PM
News IconBiogen Inc. (NASDAQ:BIIB) from Biotechnology – Todays Top Gains (NASDAQ:BIIB) - August 24 at 3:50 PM logoBiotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review (NASDAQ:BIIB) - August 24 at 3:50 PM
News IconAnalysts Valuations For Two Stocks: Biogen Inc (NASDAQ:BIIB), Campbell Soup Company (NYSE:CPB) - The Voice Registrar (NASDAQ:BIIB) - August 24 at 12:04 PM
News IconJefferies Group Reiterates Buy at Biogen Inc. (NASDAQ: BIIB) - BNB Daily (blog) (NASDAQ:BIIB) - August 24 at 12:04 PM logo9 Stocks Smart Investors Put Their Money in Last Quarter (NASDAQ:BIIB) - August 23 at 3:52 PM
News IconStock's Buzz: ACADIA Pharmaceuticals (ACAD), Biogen Inc. (BIIB ... - Newburg Press (NASDAQ:BIIB) - August 22 at 8:53 PM logoWill Biogen Idec Inc. (NASDAQ:BIIB) Hit $414 Price Target? - Investor Newswire (NASDAQ:BIIB) - August 21 at 3:43 PM logoWhat Is Mean Rating On Biogen Idec Inc. (NASDAQ:BIIB)? - Stocks Daily (NASDAQ:BIIB) - August 18 at 9:18 PM logoMorgan Stanley Chimes In On Two Healthcare Giants: Valeant Pharmaceuticals Intl Inc (VRX), Biogen Inc (BIIB) (NASDAQ:BIIB) - August 18 at 3:59 PM
News IconTop Gainers of the Day: Biogen Inc. (NASDAQ:BIIB) from Biotechnology (NASDAQ:BIIB) - August 16 at 9:04 PM logoAmid takeover rumors, Biogen gives details on hemophilia spinoff (NASDAQ:BIIB) - August 15 at 9:31 PM logoSarah Ketterer Takes 3 Positions in 2nd Quarter (NASDAQ:BIIB) - August 15 at 9:31 PM logoValeant sinks on criminal probe (NASDAQ:BIIB) - August 11 at 3:54 PM logoETF’s with exposure to Biogen, Inc. : August 11, 2016 (NASDAQ:BIIB) - August 11 at 3:54 PM logo24.8% Return Seen to Date on SmarTrend Biogen Idec Call (BIIB) (NASDAQ:BIIB) - August 11 at 11:59 AM
News IconIs Biogen Inc. (NASDAQ:BIIB), a large market cap stock a smart buy? (NASDAQ:BIIB) - August 11 at 11:59 AM logoAlliancebernstein L.P. Bought A Little More Biogen Inc. (BIIB) Stock (NASDAQ:BIIB) - August 11 at 11:59 AM logoAllergan Adds Glaucoma Treatment Maker for $95M (NASDAQ:BIIB) - August 11 at 11:59 AM logo​Here’s what we know about Shire’s cost-cutting plans for the next three years (NASDAQ:BIIB) - August 11 at 11:59 AM logoBiogen Inc: BIIB Stock Is a Biotech Standout - (NASDAQ:BIIB) - August 10 at 3:17 PM logoBiogen Inc: BIIB Stock Is a Biotech Standout (NASDAQ:BIIB) - August 10 at 11:23 AM logoMassive money outflow: Biogen Inc. (NASDAQ:BIIB) , Motorola Solutions, Inc. (NYSE:MSI) - Street Updates (NASDAQ:BIIB) - August 10 at 7:28 AM
News IconBiogen Plans to Name Hemophilia Spinoff 'Bioverativ' (NASDAQ:BIIB) - August 9 at 4:58 PM
News IconBiogen Plans to Name Hemophilia Spinoff 'Bioverativ' (NASDAQ:BIIB) - August 9 at 4:58 PM logoCan Biogen Idec Inc. (NASDAQ:BIIB) Meet Analysts Expectations? - Stocks Daily (NASDAQ:BIIB) - August 8 at 9:16 PM
News IconEye Catching Stock: Biogen Inc. (NASDAQ:BIIB) | News Oracle - News Oracle (NASDAQ:BIIB) - August 8 at 3:52 PM logoStrong Sell Calls For Biogen Idec Inc. (NASDAQ:BIIB) At 0 - Investor Newswire (NASDAQ:BIIB) - August 7 at 3:49 PM
News IconLeading stocks in today’s market: Biogen Inc. (NASDAQ:BIIB) (NASDAQ:BIIB) - August 6 at 11:34 AM
News IconBiogen Inc: Bidding War Could Send Biogen Stock Soaring - Profit Confidential (NASDAQ:BIIB) - August 5 at 3:52 PM logoBiogen: Not Your Grandmother's M&A Target (NASDAQ:BIIB) - August 5 at 3:52 PM
News IconUpdate on Biogen Inc. (NASDAQ:BIIB) for the day (NASDAQ:BIIB) - August 5 at 12:14 PM
News IconBiogen Inc: Bidding War Could Send Biogen Stock Soaring (NASDAQ:BIIB) - August 5 at 12:14 PM logoBiogen’s MS Drugs: Deadly Cash Cows? (NASDAQ:BIIB) - August 5 at 12:14 PM logoCredit Suisse Highlights The Million Dollar Question For Biogen Inc (BIIB) - Smarter Analyst (NASDAQ:BIIB) - August 4 at 9:36 PM logoCredit Suisse Highlights The Million Dollar Question For Biogen Inc (BIIB) (NASDAQ:BIIB) - August 4 at 3:56 PM logoBiogen (BIIB) Stock Slides, Reportedly Not Pursuing Sale (NASDAQ:BIIB) - August 4 at 3:56 PM logoStocks within Analysts Screening: Biogen Inc. (NASDAQ:BIIB) , Novartis AG (NYSE:NVS) - Street Updates (NASDAQ:BIIB) - August 4 at 12:26 PM logoBiogen Inc. (BIIB) is Trading Higher on Unusual Volume for August 02 - (NASDAQ:BIIB) - August 4 at 12:26 PM
News IconBlackBerry Ltd (NASDAQ:BBRY) & Biogen Inc (NASDAQ:BIIB) Stocks Alert - Money News (press release) (NASDAQ:BIIB) - August 4 at 12:26 PM logoM&A Chatter Heats Up Biogen Inc's (BIIB) Options Pits - Schaeffers Research (blog) (NASDAQ:BIIB) - August 4 at 12:26 PM logoMerrill Lynch Says the Time to Put Money Into Biotech Is Now (NASDAQ:BIIB) - August 4 at 12:26 PM


Biogen (NASDAQ:BIIB) Chart for Tuesday, August, 30, 2016

Last Updated on 8/30/2016 by Staff